Combined inhibition of EZH2 and ATM is synthetic lethal in BRCA1-deficient breast cancer

BACKGROUND: The majority of BRCA1-mutant breast cancers are characterized by a triple-negative phenotype and a basal-like molecular subtype, associated with aggressive clinical behavior. Current treatment options are limited, highlighting the need for the development of novel targeted therapies for...

Descripción completa

Detalles Bibliográficos
Autores principales: Ratz, Leonie, Brambillasca, Chiara, Bartke, Leandra, Huetzen, Maxim A., Goergens, Jonas, Leidecker, Orsolya, Jachimowicz, Ron D., van de Ven, Marieke, Proost, Natalie, Siteur, Bjørn, de Korte-Grimmerink, Renske, Bouwman, Peter, Pulver, Emilia M., de Bruijn, Roebi, Isensee, Jörg, Hucho, Tim, Pandey, Gaurav, van Lohuizen, Maarten, Mallmann, Peter, Reinhardt, Hans Christian, Jonkers, Jos, Puppe, Julian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9206299/
https://www.ncbi.nlm.nih.gov/pubmed/35715861
http://dx.doi.org/10.1186/s13058-022-01534-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9206299/
https://www.ncbi.nlm.nih.gov/pubmed/35715861
http://dx.doi.org/10.1186/s13058-022-01534-y

Ejemplares similares